Opportunity Information: Apply for RFA MH 21 110
The National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), announced this discretionary grant opportunity to fund research that can strengthen real-world suicide prevention services. The program is centered on "service-ready" tools and technologies, meaning practical resources that are already mature enough to be plugged into routine care, training, and quality improvement efforts with minimal extra development. The overall goal is to expand the availability and consistent delivery of evidence-based approaches for identifying, preventing, and treating suicidal thoughts and behaviors by supporting studies that can show, in a definitive way, whether a given tool works and how it can be implemented and sustained in typical service settings.
A key emphasis is research that sits on the effectiveness-implementation continuum. On one side, applicants can focus on developing and testing the effectiveness of optimized, service-ready tools for suicide risk identification, prevention, and treatment. On the other side, applicants can test strategies that improve adoption, implementation fidelity, and long-term sustainment of these tools, with the expectation that studies will be guided by an implementation science framework. In practice, that means NIMH is looking not only for evidence that a tool improves outcomes, but also for clear, testable plans to understand and reduce the real-world barriers that often prevent good interventions from being used correctly and consistently.
Because the initiative is explicitly aimed at practice-ready resources that can be used broadly, NIMH encourages applicants to use technology and design features that make tools scalable and resilient to "implementation drift" (the common problem where programs gradually deviate from their intended model over time). Examples of the kinds of features NIMH is signaling interest in include tools that can be integrated into clinical workflows, tools that support training and supervision, and tools that enable quality monitoring and continuous quality improvement. The announcement also stresses a deployment-focused approach, meaning the development and testing process should incorporate perspectives from the people and systems that will actually use the tool: service users (patients/clients), providers, administrators, and other stakeholders. Applicants are expected to consider system-level constraints such as staffing and workforce capacity, since these factors often determine whether an intervention can realistically be adopted and maintained.
This funding opportunity uses the R01 mechanism and is labeled "Clinical Trial Optional," indicating that applicants may propose a clinical trial if it fits their research question, but a clinical trial is not required for every project. What NIMH is clearly prioritizing under this R01, however, is effectiveness research that is statistically powered to provide a definitive answer about whether the tool or technology works. In other words, the Institute is not aiming this particular R01 at early, exploratory pilots; it is aimed at larger and more rigorous studies where the expected outcome is a clear determination of effectiveness in relevant service contexts.
The announcement also clarifies how this R01 fits into a broader set of related funding options. For earlier-stage pilot effectiveness work that focuses on feasibility, tolerability, acceptability, safety, and preliminary signals of benefit, NIMH points applicants to a separate R34 opportunity (RFA-21-111). For small business-led projects (SBIR) focused on service-ready tools and technologies for suicide prevention, NIMH points to the R43/R44 opportunity (RFA-21-112). This division highlights NIMH's intention that the R01 described here should support more mature tools that are ready for definitive effectiveness testing and real-world implementation research.
Eligibility is broad and spans many types of U.S.-based organizations, reflecting the applied public health and service delivery focus of the program. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. The opportunity also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Foreign eligibility is limited. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, are allowed, which generally means a U.S. applicant may include certain foreign activities or collaborations when they are well-justified and consistent with NIH policy.
Administrative details from the source record include the funding opportunity title "Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)," funding opportunity number RFA-MH-21-110, and CFDA number 93.242 (mental health-related NIH assistance). The agency is NIH (specifically NIMH), the funding instrument is a grant, and the activity category is health. The original closing date listed is June 15, 2022, and the record shows a creation date of November 13, 2020. The listing does not provide an award ceiling or an expected number of awards in the provided fields, so those specifics are not available from the included source data.
Taken together, this opportunity is designed for teams that already have a well-developed, practice-ready suicide prevention tool (or a near-final optimized version) and can run a rigorous, adequately powered study to prove its effectiveness, while also addressing the practical realities of implementation: uptake by providers and systems, fidelity over time, integration into workflows, and sustained use in real service settings.Apply for RFA MH 21 110
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2020-11-13.
- Applicants must submit their applications by 2022-06-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The funding opportunity is titled "Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)."
What is the funding opportunity number?
The funding opportunity number is RFA-MH-21-110.
Which agency is offering this grant?
This opportunity is offered by the National Institute of Mental Health (NIMH), which is part of the National Institutes of Health (NIH).
What type of funding mechanism is being used?
This opportunity uses the NIH R01 research project grant mechanism.
Is a clinical trial required?
No. The opportunity is labeled "Clinical Trial Optional," meaning a clinical trial may be proposed if it matches the research question, but it is not required for every application.
What is the main purpose of this grant?
The purpose is to fund research that strengthens real-world suicide prevention services by testing practical, "service-ready" tools and technologies that can be used in routine care, training, and quality improvement with minimal additional development.
What does "service-ready" mean in this announcement?
"Service-ready" refers to tools and technologies that are mature enough to be plugged into typical service settings (routine care, training, supervision, and quality improvement) without needing major new development work.
What kinds of outcomes is NIMH trying to improve?
The goal is to expand the availability and consistent delivery of evidence-based approaches for identifying, preventing, and treating suicidal thoughts and behaviors, and to support studies that can definitively determine whether a tool works in relevant service contexts.
What kind of research is NIMH prioritizing under this R01?
NIMH is prioritizing rigorous, statistically powered effectiveness research designed to provide a definitive answer about whether the tool or technology works, rather than early exploratory or pilot studies.
Are early-stage pilot studies a good fit for this R01?
This R01 is described as being aimed at larger, more rigorous studies, not early, exploratory pilots. For earlier-stage pilot effectiveness work (feasibility, acceptability, safety, preliminary signals of benefit), the announcement points applicants to a separate R34 opportunity (RFA-21-111).
How does this opportunity relate to the R34 option mentioned?
The R34 (RFA-21-111) is positioned for earlier-stage pilot effectiveness work focused on feasibility, tolerability, acceptability, safety, and preliminary benefit, whereas this R01 is positioned for definitive effectiveness testing and real-world implementation research with more mature tools.
How does this opportunity relate to the SBIR options mentioned?
For small business-led SBIR projects focused on service-ready suicide prevention tools and technologies, the announcement points to the R43/R44 opportunity (RFA-21-112). This R01 is not limited to small businesses and is intended to support definitive effectiveness and implementation research.
What does it mean that the program is on the "effectiveness-implementation continuum"?
It means projects may focus on (1) developing and testing the effectiveness of optimized, service-ready tools, (2) testing strategies to improve adoption, implementation fidelity, and sustainment of those tools, or (3) both, depending on the research aims.
What is the role of implementation science in this announcement?
When applicants propose work focused on adoption, fidelity, and sustainment, the announcement expects the study to be guided by an implementation science framework, with clear and testable plans to understand and reduce real-world barriers to correct and consistent use.
What is "implementation drift" and why does it matter here?
Implementation drift is when an intervention gradually deviates from its intended model over time in real-world settings. NIMH encourages technology and design features that help tools remain scalable and resilient to drift so they can be delivered consistently.
What kinds of tool features does NIMH highlight as valuable?
The announcement signals interest in features such as tools that integrate into clinical workflows, tools that support training and supervision, and tools that enable quality monitoring and continuous quality improvement.
What does a "deployment-focused approach" mean in this context?
It means development and testing should incorporate perspectives from the people and systems that will use the tool in practice, including service users (patients/clients), providers, administrators, and other stakeholders.
What real-world constraints should applicants consider?
Applicants are expected to consider system-level constraints such as staffing and workforce capacity, since these factors often determine whether an intervention can realistically be adopted, implemented with fidelity, and sustained.
What types of organizations are eligible to apply?
Eligibility is broad and includes many U.S.-based organizations such as state/county/local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (other than federally recognized governments); public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses.
Are specific institution types explicitly mentioned as eligible?
Yes. The opportunity explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Can non-U.S. (foreign) organizations apply as the main applicant?
No. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply.
Are any foreign activities allowed at all?
Yes. Foreign components (as defined in the NIH Grants Policy Statement) are allowed, meaning a U.S. applicant may include certain foreign activities or collaborations when well-justified and consistent with NIH policy.
What is the CFDA number for this opportunity?
The CFDA number listed is 93.242.
What is the funding instrument and activity category?
The funding instrument is a grant, and the activity category is health.
What is the application closing date shown in the source information?
The original closing date listed in the provided record is June 15, 2022.
When was this opportunity record created?
The record shows a creation date of November 13, 2020.
Does the provided listing state an award ceiling or the expected number of awards?
No. The provided fields do not include an award ceiling or an expected number of awards, so those specifics are not available from the included source data.
What kind of applicant team is this opportunity designed for?
It is designed for teams that already have a well-developed, practice-ready (or near-final optimized) suicide prevention tool and can conduct a rigorous, adequately powered study to demonstrate effectiveness, while also addressing practical implementation issues like uptake, fidelity, workflow integration, and sustainment.
Browse more opportunities from the same category: Health
Next opportunity: Countering Malign Influences Virtual Grant Program
Previous opportunity: USAID IMPROVED LEARNING OUTCOMES IN PRIMARY EDUCATION (USAID SABER)”
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 21 110
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 21 110) also looked into and applied for these:
| Funding Opportunity |
|---|
| Social Drivers of Mental Illnesses in Low- and Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional) Apply for RFA MH 21 160 Funding Number: RFA MH 21 160 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required) Apply for PAR 21 043 Funding Number: PAR 21 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) Apply for RFA MH 21 105 Funding Number: RFA MH 21 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Collaborative Clinical Vision Research : Chair's Grant (UG1-Clinical Trial Required) Apply for PAR 21 041 Funding Number: PAR 21 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) Apply for PAR 21 079 Funding Number: PAR 21 079 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required) Apply for PAR 21 042 Funding Number: PAR 21 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) Apply for PAR 21 056 Funding Number: PAR 21 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) Apply for RFA MH 21 106 Funding Number: RFA MH 21 106 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) Apply for PAR 21 059 Funding Number: PAR 21 059 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional) Apply for PAR 21 057 Funding Number: PAR 21 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiative for Maximizing Student Development (IMSD) (T32 - Clinical Trial Not Allowed) Apply for PAR 21 025 Funding Number: PAR 21 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) Apply for PAR 21 058 Funding Number: PAR 21 058 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32 - Clinical Trial Not Allowed) Apply for PAR 21 026 Funding Number: PAR 21 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) Apply for PAR 21 084 Funding Number: PAR 21 084 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trials Not Allowed) Apply for PAR 21 090 Funding Number: PAR 21 090 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional) Apply for PAR 21 073 Funding Number: PAR 21 073 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Program Project Applications (P01 Clinical Trials Optional) Apply for PAR 21 088 Funding Number: PAR 21 088 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Coordination and Evaluation Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 20 023 Funding Number: RFA RM 20 023 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program: FIRST Cohort (U54 Clinical Trial Optional) Apply for RFA RM 20 022 Funding Number: RFA RM 20 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required) Apply for PAR 21 087 Funding Number: PAR 21 087 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 21 110", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
